MOTS-c (Human)

Batch documentation

Overview

Sequence MRWQEMGYIFYPRKLR, 16 residues, encoded inside the 12S rRNA region of the human mitochondrial genome, MOTS-c is one of the better-characterised members of the mitochondrial-derived peptide (MDP) class. MDPs are a relatively recent addition to the peptide therapeutics universe: they are translated from short open reading frames sitting inside mitochondrial ribosomal RNAs, a class of peptides the textbooks did not acknowledge until the early 2010s. MOTS-c signalling itself runs retrograde, from mitochondrion to nucleus, through AMPK-axis activation; the published research portfolio spans glucose metabolism, insulin-sensitivity endpoints, exercise-capacity studies, body-weight regulation, and the broader landscape of age-related mitochondrial decline. For 503A pharmacies tracking the regulatory pipeline: MOTS-c is currently scheduled on the FDA PCAC July 2026 agenda for review against the 503A bulks list, with proposed indications covering obesity and osteoporosis. For compounding pharmacy buyers, Vialdyne releases MOTS-c acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The batch COA that comes with every lot pairs RP-HPLC peak integration with ESI-MS at the 2174.6 Da theoretical mass, with Karl Fischer water and counter-ion quantitation available on request; LC-MS/MS sequence verification is available as a documented add-on. Plasma half-life is short, on the order of minutes to a couple of hours, so MOTS-c functions as a tool for acute mitochondrial-signalling protocols rather than sustained-elevation work, repeat dosing or sustained-release formulation is required to hold biological exposure across longer windows. Four nominal strengths from 10 to 40 mg cover both aliquot-scale bench work and small-batch dispensing inside a single qualified supplier line.

Applications & buyer fit

Mitochondrial-targeted peptides ship primarily to research labs studying OXPHOS, ROS biology, and mitochondrial dysfunction in disease models. The lipophilic / cationic character that drives mitochondrial accumulation also makes these peptides somewhat oxidation-prone in solution, working stocks should be prepared fresh or held at -80 °C rather than -20 °C when the workflow permits.

Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.

Specifications

CAS

1627580-64-6

Sequence

MRWQEMGYIFYPRKLR

Purity (HPLC)

≥ 99.0%

Strength

10 mg – 40 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 30-60 minutes

MOQ

On request

Lead time

10–18 days

Storage

-20°C, protect from light

Certificate of Analysis

Representative COA previews for MOTS-c (Human); request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

MOTS-c (Human)

VD260428-MS10139 · 99.48%

VerifiedRequest full COA →

MOTS-c (Human)

VD260428-MOT140 · 99.66%

VerifiedRequest full COA →

MOTS-c (Human)

VD260428-MS20141 · 99.40%

VerifiedRequest full COA →

MOTS-c (Human)

VD260428-MS40142 · 99.01%

Independent analytical testing

Product- and strength-matched first-page previews are shown separately from Vialdyne's lot-specific Batch COAs. Reference the report number when requesting the complete, high-resolution file from sales.

Third-party testView report record →

MOTS-C

10 mg · HPLC / MS

MS10-20260810S6595

Regulatory note

MOTS-c is presently before the FDA's PCAC (July 2026) for addition to the 503A bulks list, the proposed indications being obesity and osteoporosis.

Selected literature

1. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470.
3. Kim SJ, Miller B, Mehta HH, Xiao J, Wan J, Arpawong TE, Yen K, Cohen P. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019;7(13):e14171.
4. Wan W, Zhang L, Lin Y, Rao X, Wang X, Hua F, Ying J. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. 2023;21:36.
5. Kumagai H, Kim SJ, Miller B, et al. MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience. 2024;27(11):111212.
6. Pham T, Taberner A, Hickey A, Han JC. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Front Physiol. 2025;16:1602271.

Frequently asked questions